多发性骨髓瘤患者微小RNA-203a表达水平及其临床意义

Objective To investigate the relationship between the level of microRNA-203a (miRNA-203a) and immunoglobulin translocations and the prognosis value on MM patients. Methods Bone marrow samples from 84 newly diagnosed MM patients were collected, 14q32 translocation were analyzed by interphase flurescence in situ hybridization in sorted CD138 positive cells. The expressions of miRNA-203a and oncogene c-Abl in plasma cells were measured by quantitative real-time PCR. Survival analysis was determined using the Kaplan-Meier method, with the differences between curves analyzed via a log-rank test and the generalized Wilcoxon procedure. Results Of the 84 MM patients, 14q32 translocation was detected in 54 (65.1%) patients. The median levels of miRNA-203a in MM patients with or without 14q32 translocation were not significantly different. With the median follow-up of 21 (1～82.5) months , the median duration of progression-free survival of patients with low expression level of miRNA-203a was significantly shorter than those with high expression level of miRNA-203a. Oncogene c-Abl expression in MM patients with low level of miRNA-203a was significantly higher than those with high level of miR-203a. Conclusions Low expression of miRNA-203a was associated with poor prognosis in MM patients. The level of miRNA-203a was associated with 14q32 translocation, and the effect of miRNA-203a on the progress of MM might be targeted in c-Abl oncogene.